Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Pneumococcal Polysaccharide Vaccine Market by Type (Single Dose Vial, Pre-Filled Syringe), By Application (Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Pneumococcal Polysaccharide Vaccine Market by Type (Single Dose Vial, Pre-Filled Syringe), By Application (Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 139280 3300 Pharma & Healthcare 377 248 Pages 4.9 (42)

Market Overview:

The global pneumococcal polysaccharide vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of pneumococcal diseases, rising demand for pneumococcal polysaccharide vaccines due to their safety and efficacy, and growing awareness about preventive measures against pneumococcal diseases. However, the high cost of these vaccines may restrain the growth of this market during the forecast period. Based on type, the global pneumococcal polysaccharide vaccine market is segmented into single dose vial and pre-filled syringe. The single dose vial segment is expected to account for a larger share of the global market in 2018 owing to its lower cost as compared with pre-filled syringes. Based on application, this market is divided into children (2-10 years), adults (10-64 years), and geriatric patients (more than 65 years).

Global Pneumococcal Polysaccharide Vaccine Industry Outlook

Product Definition:

Pneumococcal polysaccharide vaccine is a vaccine used to prevent pneumococcal disease, which is an infection caused by the Streptococcus pneumoniae bacteria. The vaccine contains purified polysaccharides from the S. pneumoniae bacteria, and it works by stimulating the body's immune system to produce antibodies against these polysaccharides. These antibodies help protect against infection with S. pneumoniae bacteria.

Single Dose Vial:

Single dose vial is a packaging type used for the storage of liquid vaccines. It is mostly used for the storage and delivery of pneumococcal polysaccharide vaccine. The single-dose vials are made up of plastic or glass and are available in different sizes, which can store different volumes of vaccines. They help in delivering each dose accurately at desired intervals with better safety features as compared to other traditional systems such as ampoules or bottles that deliver all doses at once.

Pre-Filled Syringe:

The pre-filled syringe is a device used to inject vaccines. It has gained popularity in the past few years due to its safety and ease of use. The pre-filled syringes are made up of plastic or metal and are available in different sizes ranging from 0.5 ml to 10 ml with various needle types including straight, bent, and curved needles.

Application Insights:

Based on the application, the global pneumococcal polysaccharide vaccine market is segmented into children (2-10 age), adult (10-64 age) and geriatric population above 65 years. The geriatric population segment held a major share of over 40% in 2017 owing to increasing prevalence of chronic diseases such as diabetes and pneumonia. Moreover, this segment is anticipated to witness lucrative growth during the forecast period due to rising number of older people worldwide.

The global PCP vaccine market witnessed significant growth in recent years owing to its usage for prevention against bacterial pneumonia among young children as well as adults. This preventive measure has led to reduced hospital admissions and deaths caused by Pneumonia among both these groups globally which supports further development of this product line for wider applications across all ages globally.

Regional Analysis:

North America dominated the global market in 2017. The rising prevalence of pneumococcal disease, increasing number of government initiatives to raise awareness about the vaccine, and high investment by key players in this region are some factors contributing to its largest share. In addition, a favorable reimbursement scenario is also expected to drive growth during the forecast period.

Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in immunization activities against pneumococcal diseases coupled with growing healthcare expenditure levels and improved access for people living in remote areas. Moreover, increasing foreign direct investments coupled with supportive policies implemented by governments towards improving public health infrastructure will further fuel regional demand during the forecast period.

Growth Factors:

  • Increasing incidence of pneumococcal infections: The global incidence of pneumococcal infections is increasing due to the spread of the disease in developing countries and the emergence of antibiotic-resistant strains. This is expected to drive demand for pneumococcal polysaccharide vaccines.
  • Growing awareness about pneumococcal diseases: There is growing awareness among people about the risks and symptoms associated with pneumococcal diseases, which is expected to boost demand for pneumococcal polysaccharide vaccines.
  • Rising number of elderly population: The number of elderly people is increasing globally, which will lead to an increase in cases of pneumonia caused by Streptococcus pneumoniae bacteria – a major target for vaccination with PPV23 vaccine. This will fuel growth in the PPV23 vaccine market over the forecast period.
  • Technological advancements in vaccine production: There has been significant progress made in technology used for manufacturing vaccines, which has led to an increase in production capacity and reduction in costs – driving down prices and making these products more affordable globally. This trend is anticipated to continue over the next few years, propelling growth prospects for the PPV23 vaccine market . 5) Expanding distribution networks: Pharmaceutical companies are expanding their distribution networks across regions, thereby enabling wider access to these products

Scope Of The Report

Report Attributes

Report Details

Report Title

Pneumococcal Polysaccharide Vaccine Market Research Report

By Type

Single Dose Vial, Pre-Filled Syringe

By Application

Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)

By Companies

Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd, ...

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Pneumococcal Polysaccharide Vaccine Market Report Segments:

The global Pneumococcal Polysaccharide Vaccine market is segmented on the basis of:


Single Dose Vial, Pre-Filled Syringe

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Children (2-10 Age), Adult (10-64 Age), Geriatric (More Than 65 Age)

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Merck & Co., Inc.
  2. Pfizer Inc.
  3. Glaxosmithkline Plc.
  4. Sanofi Pasteur
  5. China National Biotec Group
  6. Astellas Pharma Inc
  7. Serum Institute of India Pvt. Ltd
  8. ...

Global Pneumococcal Polysaccharide Vaccine Market Overview

Highlights of The Pneumococcal Polysaccharide Vaccine Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Single Dose Vial
    2. Pre-Filled Syringe
  1. By Application:

    1. Children (2-10 Age)
    2. Adult (10-64 Age)
    3. Geriatric (More Than 65 Age)
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Pneumococcal Polysaccharide Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Pneumococcal Polysaccharide Vaccine Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Pneumococcal polysaccharide vaccine (PPV) is a vaccine used to prevent pneumococcal infections. PPV is made from the capsular polysaccharides of Streptococcus pneumoniae, and it helps protect against pneumococcal infections in people aged 2 years or older. PPV is given as a shot in the arm. It can help prevent serious pneumococcal infections, including meningitis, pneumonia, and death.

Some of the key players operating in the pneumococcal polysaccharide vaccine market are Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd.

The pneumococcal polysaccharide vaccine market is expected to register a CAGR of 7.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Pneumococcal Polysaccharide Vaccine Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Pneumococcal Polysaccharide Vaccine Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Pneumococcal Polysaccharide Vaccine Market - Supply Chain
   4.5. Global Pneumococcal Polysaccharide Vaccine Market Forecast
      4.5.1. Pneumococcal Polysaccharide Vaccine Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Pneumococcal Polysaccharide Vaccine Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Pneumococcal Polysaccharide Vaccine Market Absolute $ Opportunity

5. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      5.3.1. Single Dose Vial
      5.3.2. Pre-Filled Syringe
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      6.3.1. Children (2-10 Age)
      6.3.2. Adult (10-64 Age)
      6.3.3. Geriatric (More Than 65 Age)
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029

9. North America Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      9.4.1. Children (2-10 Age)
      9.4.2. Adult (10-64 Age)
      9.4.3. Geriatric (More Than 65 Age)
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      9.7.1. Single Dose Vial
      9.7.2. Pre-Filled Syringe
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029

10. Latin America Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      10.4.1. Children (2-10 Age)
      10.4.2. Adult (10-64 Age)
      10.4.3. Geriatric (More Than 65 Age)
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      10.7.1. Single Dose Vial
      10.7.2. Pre-Filled Syringe
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Pneumococcal Polysaccharide Vaccine Demand Share Forecast, 2019-2029

11. Europe Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      11.4.1. Children (2-10 Age)
      11.4.2. Adult (10-64 Age)
      11.4.3. Geriatric (More Than 65 Age)
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      11.7.1. Single Dose Vial
      11.7.2. Pre-Filled Syringe
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029

12. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      12.4.1. Children (2-10 Age)
      12.4.2. Adult (10-64 Age)
      12.4.3. Geriatric (More Than 65 Age)
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      12.7.1. Single Dose Vial
      12.7.2. Pre-Filled Syringe
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029

13. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Application
      13.4.1. Children (2-10 Age)
      13.4.2. Adult (10-64 Age)
      13.4.3. Geriatric (More Than 65 Age)
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Pneumococcal Polysaccharide Vaccine Market Size and Volume Forecast by Type
      13.7.1. Single Dose Vial
      13.7.2. Pre-Filled Syringe
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Pneumococcal Polysaccharide Vaccine Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Pneumococcal Polysaccharide Vaccine Market: Market Share Analysis
   14.2. Pneumococcal Polysaccharide Vaccine Distributors and Customers
   14.3. Pneumococcal Polysaccharide Vaccine Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Merck & Co., Inc. Overview Financials Developments Strategic Outlook
      14.4.2. Pfizer Inc. Overview Financials Developments Strategic Outlook
      14.4.3. Glaxosmithkline Plc. Overview Financials Developments Strategic Outlook
      14.4.4. Sanofi Pasteur Overview Financials Developments Strategic Outlook
      14.4.5. China National Biotec Group Overview Financials Developments Strategic Outlook
      14.4.6. Astellas Pharma Inc Overview Financials Developments Strategic Outlook
      14.4.7. Serum Institute of India Pvt. Ltd Overview Financials Developments Strategic Outlook
      14.4.8. ... Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us